Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Lupus Nephritis | Research

Effects of receiving renal biopsy on the prognosis of chronic kidney disease patients with impaired renal function

Authors: Tianyi Zhang, Xiaoqian Yang, Minfang Zhang, Wenyan Zhou, Yan Jin, Hang Zhou, Yin Zhou, Qin Wang, Shan Mou

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

Impaired renal function was not a recognized indication for renal biopsy. The effects of receiving renal biopsy on the renal functional prognosis for chronic kidney disease (CKD) patients with impaired renal function need to be explored.

Methods

This study retrospectively enrolled 300 renal function impaired CKD patients in Renji Hospital from January 2015 to December 2017, 150 of them received percutaneous renal biopsy while the others did not. The endpoint was ≥ 50% estimated glomerular filtration rate (eGFR) decline from baseline or development of end-stage renal disease (ESRD). Kaplan-Meier analysis with log-rank test was performed to compare the renal survival probability between patients receiving renal biopsy or not. Univariate and multivariate analysis with Cox regression were conducted with predictors of poor renal outcomes in the study cohort.

Results

The median follow-up period was 37.6 months. During the follow-up period, the eGFR of the biopsy group increased from 52.2 ± 14.4 to 67.4 ± 37.8 ml/min/1.73 m², but decreased from 55.3 ± 17.1 to 29.8 ± 19.1 ml/min/1.73 m² in the non-biopsy group. Patients who received renal biopsy had significantly higher renal survival probability (P < 0.001). Cox regression analysis revealed that 24-hour urine protein excretion (24 h UPE) more than 1 g/d was an independent predictor for poor renal outcomes in the non-biopsy group but not in the renal biopsy group (HR = 1.719, P = 0.040).

Conclusion

CKD patients with impaired renal function are recommended to receive renal biopsy to make pathological diagnoses, especially for those with the 24-hour urine protein excretion more than 1 g/d.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.CrossRefPubMed Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.CrossRefPubMed
2.
go back to reference Gonzalez-Espinoza L, Ortiz A. 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. Clin Kidney J, 2015. 8(3): p. 243-7. Gonzalez-Espinoza L, Ortiz A. 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. Clin Kidney J, 2015. 8(3): p. 243-7.
3.
go back to reference Dhaun N, Bellamy CO, Cattran DC, et al. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014;85(5):1039–48.CrossRefPubMed Dhaun N, Bellamy CO, Cattran DC, et al. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014;85(5):1039–48.CrossRefPubMed
4.
go back to reference Alexopoulos E. How important is renal biopsy in the management of patients with glomerular diseases? Nephrol Dial Transplant, 2001. 16 Suppl 6: p.83–5. Alexopoulos E. How important is renal biopsy in the management of patients with glomerular diseases? Nephrol Dial Transplant, 2001. 16 Suppl 6: p.83–5.
5.
go back to reference Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis. 2000;35(3):448–57.CrossRefPubMed Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis. 2000;35(3):448–57.CrossRefPubMed
6.
go back to reference Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225–36.CrossRefPubMed Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225–36.CrossRefPubMed
7.
go back to reference Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015–From epidemiology to evidence-based indications. Am J Nephrol. 2016;43(1):1–19.CrossRefPubMed Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015–From epidemiology to evidence-based indications. Am J Nephrol. 2016;43(1):1–19.CrossRefPubMed
8.
go back to reference Joseph AJ, Compton SP, Holmes LH, et al. Utility of percutaneous renal biopsy in chronic kidney disease. Nephrol (Carlton). 2010;15(5):544–8.CrossRef Joseph AJ, Compton SP, Holmes LH, et al. Utility of percutaneous renal biopsy in chronic kidney disease. Nephrol (Carlton). 2010;15(5):544–8.CrossRef
10.
go back to reference Hogan JJ, Mocanu M, Berns JS. The native kidney biopsy: update and evidence for best practice. Clin J Am Soc Nephrol. 2016;11(2):354–62.CrossRefPubMed Hogan JJ, Mocanu M, Berns JS. The native kidney biopsy: update and evidence for best practice. Clin J Am Soc Nephrol. 2016;11(2):354–62.CrossRefPubMed
11.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD Word Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Word Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
12.
go back to reference K/DOQI clinical. Practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. K/DOQI clinical. Practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
13.
go back to reference Levey AS, Coresh J, Greene T, et al. Expressing the modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–72.CrossRefPubMed Levey AS, Coresh J, Greene T, et al. Expressing the modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–72.CrossRefPubMed
14.
go back to reference Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73(3):404–15.CrossRefPubMed Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73(3):404–15.CrossRefPubMed
15.
go back to reference Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483–95.CrossRefPubMed Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483–95.CrossRefPubMed
16.
go back to reference Turin TC, James M, Ravani P, et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol. 2013;24(10):1661–7.CrossRefPubMedPubMedCentral Turin TC, James M, Ravani P, et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol. 2013;24(10):1661–7.CrossRefPubMedPubMedCentral
17.
go back to reference Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–27.CrossRefPubMedPubMedCentral Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–27.CrossRefPubMedPubMedCentral
19.
go back to reference Chakera A, MacEwen C, Bellur SS, et al. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 2016;29(3):367–75.CrossRefPubMed Chakera A, MacEwen C, Bellur SS, et al. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 2016;29(3):367–75.CrossRefPubMed
20.
go back to reference Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification Working Group. Kidney Int. 2017;91(5):1014–21.CrossRefPubMed Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification Working Group. Kidney Int. 2017;91(5):1014–21.CrossRefPubMed
21.
go back to reference Parikh SV, Alvarado A, Malvar A, et al. The kidney biopsy in Lupus Nephritis: past, Present, and Future. Semin Nephrol. 2015;35(5):465–77.CrossRefPubMed Parikh SV, Alvarado A, Malvar A, et al. The kidney biopsy in Lupus Nephritis: past, Present, and Future. Semin Nephrol. 2015;35(5):465–77.CrossRefPubMed
22.
go back to reference De Rosa M, Toblli J, De Rosa G et al. Could proteinuria less than 500 mg/d be an actual indicator of lupus nephritis biopsy? J Am Soc Nephrol. 2013; Annual Meeting Abstracts: PO720. De Rosa M, Toblli J, De Rosa G et al. Could proteinuria less than 500 mg/d be an actual indicator of lupus nephritis biopsy? J Am Soc Nephrol. 2013; Annual Meeting Abstracts: PO720.
Metadata
Title
Effects of receiving renal biopsy on the prognosis of chronic kidney disease patients with impaired renal function
Authors
Tianyi Zhang
Xiaoqian Yang
Minfang Zhang
Wenyan Zhou
Yan Jin
Hang Zhou
Yin Zhou
Qin Wang
Shan Mou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03097-2

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine